The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma.

The U.S. health regulator has approved GSK's add-on treatment for severe asthma, offering a less frequently dosed option, but ...

The U.S. Food and Drug Administration has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for severe ...

If the FeNO level is not raised, it is recommended that the patient be offered either a Long-Acting Muscarinic Antagonist (LAMA) or a Leukotriene Receptor Antagonist (LTRA) on top of a moderate-dose ...

WASHINGTON - The Food and Drug Administration has approved Exdensur as an add-on maintenance treatment for patients aged 12 ...

The FDA approved depemokimab as an add-on maintenance treatment in patients aged at least 12 years with severe asthma and an ...

The wheezing. The coughing. The extreme and sudden shortness of breath. These are symptoms that are attached to asthma, which is a surprisingly common condition. According to the Asthma and Allergy ...

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Exdensur ...

* Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma - ...

There’s no cure for childhood asthma, and the condition won’t resolve as a child ages. However, treatments such as inhalers and oral medications can help keep the symptoms under control. Share on ...

Due to eczema, asthma and allergies being so closely connected, coordinated care plays a critical role in long-term outcomes. Allergists are uniquely trained to manage these conditions together rather ...